Original Research Article

Maternal and fetal outcome of pregnancies complicated with thrombocytopenia

Atul Padmawar1,*, Priti Ghanshyam Verma1, Geetanjali Khadse1, Sristi Ram Dhishana1

1Dept. of Obstetrics and Gynaecology, Shri Vasantrao Naik Govt Medical College, Yavatmal, Maharashtra, India

Thrombocytopenia is defined as a platelet count below the lower limit of normal range (typically < 150,000/microL). It is second only to anemia as the most common hematological abnormality encountered during pregnancy. Thrombocytopenia complicates about 7-8% of all pregnancies, especially in third trimester; it most frequently represents a complication not requiring treatment. Evaluation and management of thrombocytopenia during pregnancy and postpartum may be challenging because there are many potential causes, some directly related to pregnancy and some unrelated. For many causes there are no diagnostic laboratory tests.

This topic reviews our approaches to determining causes of thrombocytopenia in a pregnant women and its impact on newborns while looking to stratify the risk according to etiology and severity of parturient’s hematological condition.

In our study Gestational thrombocytopenia was the commonest cause of thrombocytopenia with incidence of 70%, followed by Preeclampsia (22%), HELLP (4%), ITP (2%) and Dengue (2%).

Gestational thrombocytopenia is the commonest cause of thrombocytopenia and may not be related to adverse pregnancy outcome, thus can be treated as benign condition. Clinical assessment is most important factor for evaluating a patient with thrombocytopenia.

Monitoring of platelet count of pregnant women should be a routine at antenatal visits for timely diagnosis and to achieve favorable feto-maternal outcome in all types of thrombocytopenia. Neonatal platelet count should be done in all mothers diagnosed with thrombocytopenia.

After detailed evaluation of the data, we came to the conclusion that with proper care and precautions, readiness to deal with complications, thrombocytopenia does not pose significant impact on maternal and fetal morbidity and mortality when compared to normal population.

© This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

1. Introduction

Thrombocytopenia is defined as a platelet count below the lower limit of normal range (typically < 150,000/microL).1 It is second only to anemia as the most common hematological abnormality encountered during pregnancy. Thrombocytopenia complicates about 7-8% of all pregnancies, especially in third trimester; it most frequently represents a complication not requiring treatment.2 Evaluation and management of thrombocytopenia during pregnancy and postpartum may be challenging because there are many potential causes, some directly related to pregnancy and some unrelated. For many causes there are no diagnostic laboratory tests.

This topic reviews our approaches to determining causes of thrombocytopenia in a pregnant women and its impact on newborns while looking to stratify the risk according to etiology and severity of parturient’s hematological condition.
2. Aims and Objectives
To assess the maternal and fetal outcomes among women presenting with thrombocytopenia.

3. Materials and Methods
3.1. Type of study
Prospective observational study.

3.2. Study setting
Department of Obstetrics and Gynaecology at Shri Vasantrao Naik Government College, Yavatmal, Maharashtra, India.

3.3. Study population
All consenting women delivered at Shri Vasantrao Naik Government Medical College Yavatmal.

3.4. Study duration
6 Months (July 2019 to December 2019).

We conducted the prospective study of 1470 pregnant women admitted consecutively during a six-month period. Out of this 100 where diagnosed with thrombocytopenia. The causes of thrombocytopenia were studied. Maternal outcomes such as mode of delivery, any postpartum haemorrhage, number of blood and blood products transfusions given were recorded. Also neonatal outcomes regarding NICU admission and platelet count in neonate were studied.

Study group comprised pregnant woman with platelet count below 150000.

For comparison, we used to control lot- patients with uncomplicated pregnancies and without thrombocytopenia.

Diagnosis of thrombocytopenia was established using criteria from international consensus. pre-eclampsia was identified as elevated BP 140 /90 mm Hg and proteinuria (> 300mg/ 24 hr) after 20 weeks of pregnancy. HELLP syndrome was diagnosed in the presence of hemolysis, elevated liver enzyme levels and low platelet count.

3.5. Statistical analysis
Standard statistic methods were used for analysing the data.

4. Results and Conclusions
At delivery, the distribution of platelet count in womens with uncomplicated singleton pregnancy was as follows:

1. 100 out of 1470 women had platelet count less than 150,000/ microL, which is 6.8%.
2. Mild thrombocytopenia (150,000- 100,000) - 50%.
3. Moderate thrombocytopenia (50,000- 100,000) - 36%.
4. Severe thrombocytopenia (less than 50,000) - 14%.

4.1. Causes
1. Gestational hypertension is the most common cause accounting for 70%.
2. Preeclampsia 22%.
3. HELLP 4%.
4. ITP 2%.
5. Dengue 2%.

4.2. Maternal outcomes

| Table 1: Mode of delivery | Cases | Controls |
|--------------------------|-------|----------|
| Vaginal delivery         | 74    | 119      |
| Cesarean section         | 26    | 251      |

Value is 0.078 in (insignificant)

| Table 2: Blood requirement | Cases | Control |
|---------------------------|-------|---------|
| Needed                    | 20    | 192     |
| Not needed                | 80    | 1178    |

Value is 0.134 (insignificant)

| Table 3: Postpartum Hemorrhage | Cases | Control |
|-------------------------------|-------|---------|
| Yes                           | 12    | 92      |
| No                            | 88    | 1278    |

Value is 0.07 (insignificant) There is no increase in PPH due to thrombocytopenia

4.3. Neonatal outcomes

| Table 4: NICU Admissions | Cases | Controls |
|--------------------------|-------|----------|
| Baby admitted            | 10    | 73       |
| Healthy                  | 90    | 1297     |

Value is 0.08 (insignificant)

8% neonates are admitted due to jaundice and 2% due to fetal distress in study group.

| Table 5: Neonates affected with thrombocytopenia | Cases | Controls |
|--------------------------------------------------|-------|----------|
| Thrombocytopenia                                | 2     | 7        |
| Normal platelet count                           | 98    | 1363     |

P value is 0.065 (insignificant)
5. Discussion

This study’s objective was to determine the relationship between maternal thrombocytopenia and neonatal complications. We look for associations between the severity of the hematological condition, as well as its etiology.

Most cases of low platelet count were mild (50%). As expected this patients were not at risk of either neonatal conditions. The maternal blood test showed no supplementary abnormalities (except for lower platelet count); no maternal clinical complications were noted.

We encountered 36% cases of moderate thrombocytopenia and 14% cases of severe thrombocytopenia. Parnas et al. observed that patients with moderate to severe thrombocytopenia have higher rates of preterm deliveries (<37 week), with a RR of 3.5. Kam et al. associated thrombocytopenia complicating pregnancy with adverse neonatal outcome.4

Regarding etiology, gestational thrombocytopenia had the higher incidence (70%). However, just as other studies have proved,5 this condition was not associated with pregnancy-related complications.

Preeclampsia accounted for 22% cases. Recent studies proved that hypertensive disorders of pregnancy are associated with increased risk of maternal- perinatal advance outcome.5-8 HELLP syndrome is another factor that the literature incriminates for increased neonatal mortality and morbidity.9,10 For patients with HELLP syndrome, Kändler et al. found with a mean age of birth of 33 weeks and a mean birth weight of 1671 g and Ben Letaifa et al. reported a mean age of 32.4 weeks and a mean weight of 1250 g.11

In our study 74 subjects had delivered by LSCS and 26 patients delivered vaginally which was similar to study by Singh et al (LSCS 36% and FTND 64%) and Vyas et al. (LSCS 37% and FTND 63%) and Ruggieri et al. (LSCS 20% and FTND 80%).12,13 In the present study 20 patients required blood transfusion. However the need of blood transfusion was higher in the studies by Paranas et al. (LSCS 20% and FTND 80%) and Dwivedi et al. (9%).14

In our study 10 neonates required NICU admissions, among which 8% was due to neonatal jaundice and 2% due to fetel distress. In the study conducted by Vyas et al. 13.02% neonates were admitted to NICU.15

In the present study, only 2 neonates had fetal thrombocytopenia, while in the study by Singh et al. incidence was 1.09% which was similar to our study.13 Also, in our study only 12 patients had PPH.

6. Conclusion

In our study Gestational thrombocytopenia was the commonest cause of thrombocytopenia with incidence of 70%, followed by Preeclampsia (22%), HELLP (4%), ITP (2%) and Dengue (2%).

Gestational thrombocytopenia is the commonest cause of thrombocytopenia and may not be related to adverse pregnancy outcome, thus can be treated as benign condition. Clinical assessment is most important factor for evaluating a patient with thrombocytopenia.

Monitoring of platelet count of pregnant women should be a routine at antenatal visits for timely diagnosis and to achieve favorable feto- maternal outcome in all types of thrombocytopenia. Neonatal platelet count should be done in all mothers diagnosed with thrombocytopenia.

After detailed evaluation of the data, we came to the conclusion that with proper care and precautions, readiness to deal with complications, thrombocytopenia does not pose significant impact on maternal and fetal morbidity and mortality when compared to normal population.

7. Source of Funding

None.

8. Conflict of Interest

None.

References

1. Kadir R, McLintock C. Thrombocytopenia and Disorders of Platelet Function in Pregnancy. Semin Thromb Hemost. 2011;37(06):640–52. doi:10.1055/s-0031-1291374
2. Bockenstedt PL. Thrombocytopenia in Pregnancy. Hematol Oncol Clin N Am. 2011;25(2):293–310. doi:10.1016/j.hoc.2011.01.004
3. Parnas M, Sheiner E, Vardi I, Burstein E, Ternahu A, Levi I, et al. Moderate to severe thrombocytopenia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2006;128(1-2):163-8. doi:10.1016/j.ejogrb.2005.12.031
4. Kam PCA, Thompson SA, Liew ACS. Thrombocytopenia in the parturient. Anaesth. 2004;59(3):255–64. doi:10.1111/j.1365-2044.2004.04578.x
5. McCrae KR, Bussel JB, Mannucci PM, Remuzzi G, Cines DB. Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. Hematol Oncol Clin Exp Obstet Gynecol. 2001;15(1):53–61. doi:10.1016/s0891-5845(01)00012-8
6. Erdemoglu M, Kuyumcuoglu U, Kale A, Akdeniz N. Factors affecting maternal and perinatal outcomes in HELLP syndrome: evaluation of 126 cases. Clin Exp Obstet Gynecol. 2010;37:213–6.
7. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome. A seven year experience. Ann Fr Anesth Reanim. 2000;19:712–8.
8. Yusuf S, Hawken S, Ounpuu S, Bucala R, Dans T, Deiss R, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2004;364(9441):937–52. doi:10.1016/s0140-6736(04)16085-7
9. Ruggieri E, Puglisi F, Festa M, Pugliese D, D’Andrea A, De Luca G, et al. Moderate to severe thrombocytopenia during pregnancy: a seven year experience of a tertiary care center. Arch Gynecol Obstet. 2005;273(1):43–9. doi:10.1007/s00404-005-0741-3
10. Aslan H, Gulp A, Cebeci A. Neonatal Outcome in Preganacies after Preterm Delivery for HELLP Syndrome. Gynecol Obstet Investig. 2004;58(2):96–9. doi:10.1007/s00404-003-0059-7
11. Ruggieri E, Puglisi F, Festa M, Pugliese D, D’Andrea A, De Luca G, et al. Moderate to severe thrombocytopenia during pregnancy: a seven year experience of a tertiary care center. Arch Gynecol Obstet. 2005;273(1):43–9. doi:10.1007/s00404-005-0741-3
12. Yücesoy G, Özkan S, Bodur H, Tan T, Çalışkan E, Vural B, et al. Neonatal mortality when compared to normal population. Adv Anesth Reanim. 2000;19:712–8.
12. Vyas R, Shah S, Yadav P, Patel U. Comparative In our study the incidence of thrombocytopenia was study of mild versus moderate to severe 8.4%. Gestational thrombocytopenia was the commonest thrombocytopenia in third trimester of pregnancy in cause with incidence of 68.2%, followed by PIH (26.3%), a tertiary care hospital. *NHL J Med ITP*. 2014;3(1):8–11.

13. Singh N, Amita D, Uma S, Tripathi AK, Sankhwar P. Prevalence and Characterization of Thrombocytopenia in Pregnancy in Indian Women. *Indian J Hematol Blood Trans fus*. 2012;28(2):77–81.

14. Dwivedi P, Puri M, Nigam A, Agarwal K. The normal range of platelet count in non-pregnant Fetomaternal outcome in pregnancy with severe women is 1,50,000/μL to 4,00,000/μL. It decreases in thrombocytopenia. *Eur Rev Med Pharmacol Sci*. 2012;16(11):1563–6.

15. Vyas R, Shah S, Yadav P, Patel U. Comparative In our study the incidence of thrombocytopenia was study of mild versus moderate to severe 8.4%. Gestational thrombocytopenia was the commonest thrombocytopenia in third trimester of pregnancy in cause with incidence of 68.2%, followed by PIH (26.3%), a tertiary care hospital. *NHL J Med ITP*. 2014;3(1):8–11.

**Author biography**

**Atul Padmawar**, Associate Professor

**Priti Ghanshyam Verma**, PG Student

**Geetanjali Khadse**, Senior Resident

**Sristi Ram Dhishana**, PG Student

---

**Cite this article:** Padmawar A, Verma PG, Khadse G, Dhishana SR. Maternal and fetal outcome of pregnancies complicated with thrombocytopenia. *Indian J Obstet Gynecol Res* 2020;7(4):540-543.